All In Biotech

Drug Trial Radar · NCT06451770

Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia

A Phase 1b Single Ascending Dose Study to Evaluate the Safety of VERVE-201 in Patients With Refractory Hyperlipidemia

Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

132

Planned (sponsor's estimate)

Start

Oct 30, 2024

Primary completion

Dec 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Jun 11, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

VT-20101 is an Open-label, Phase 1b, Single-ascending dose study that will evaluate the safety of VERVE-201 administered to patients with Refractory Hyperlipidemia. VERVE-201 uses base-editing technology designed to inactivate the expression of the ANGPTL3 gene in the liver and lower circulating low-density lipoprotein cholesterol (LDL-C) and triglycerides. This study is designed to determine the safety and pharmacodynamic profile of VERVE-201 in this patient population.

Conditions

  • Hypercholesterolemia
  • Hypertriglyceridemia
  • Refractory Hyperlipidemia

Interventions

  • VERVE-201Drug

    Intravenous (IV) infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)Time frame: Up to Day 365

Locations

18 sites in 6 countries. Site status is shown where the registry gives one.

  • Clinical Study Center

    Garden Grove, California · Recruiting

  • Clinical Study Center

    Clearwater, Florida · Recruiting

  • Clinical Study Center

    Miami Lakes, Florida · Recruiting

  • Clinical Study Center

    Port Orange, Florida · Recruiting

  • Clinical Study Center

    New York, New York · Recruiting

  • Clinical Study Center

    Adelaide, Australia · Recruiting

  • Clinical Study Center

    Melbourne, Australia · Recruiting

  • Clinical Study Center

    Chicoutimi, Canada · Recruiting

  • Clinical Study Center

    Montreal, Canada · Recruiting

  • Clinical Study Center

    Toronto, Canada · Recruiting

  • Clinical Study Center

    Amsterdam, Netherlands · Recruiting

  • Clinical Study Center

    Rotterdam, Netherlands · Recruiting

  • Clinical Study Center

    Cape Town, South Africa · Recruiting

  • Clinical Study Center

    Johannesburg, South Africa · Recruiting

  • Clinical Study Center

    Liverpool, United Kingdom · Recruiting

  • Clinical Study Center

    London, United Kingdom · Recruiting

  • Clinical Study Center 2

    Manchester, United Kingdom · Recruiting

  • Clinical Study Center

    Manchester, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.